Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences

London, UK, 01 October 2025 – Tangram Therapeutics (formerly e-therapeutics), a company committed to uniting computation and RNAi to make better medicines faster, today announced its participation in the following scientific and investor conferences:

Investor Conferences

H.C. Wainwright Genetic Medicines Virtual Conference
Date: 15th October 2025

H.C. Wainwright Liver Diseases Virtual Conference
Date: 22nd October 2025

Wells Fargo Virtual Private Biopharma Symposium
Date: 5th November 2025

Scientific Conferences

BiotechX Europe

Title: Computational Approaches for Target Discovery
Format: Oral presentation
Date: 6th October 2025

Title: Revolutionizing Drug Discovery: AI-Powered Identification and Evaluation of Therapeutic Targets
Format: Oral presentation
Date: 7th October 2025

Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Title: A Machine Learning Approach to Designing Potent and Specific GalOmic siRNA Sequences Without In Vitro Screening
Format: Poster presentation
Date: 21st October 2025

TIDES Europe

Title: TGM-312 – A Novel GalOmic GalNAc-siRNA for the Treatment of MASH
Format: Oral presentation
Date: 12th November 2025

About Tangram Therapeutics

Tangram Therapeutics (formerly e-therapeutics) is a biotech company committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster. We are advancing a pipeline of GalOmic RNAi medicines for a broad range of diseases with high unmet need. Our lead programs TGM-312 for MASH and TGM-148 for bleeding disorders are approaching the clinic, on track for regulatory submissions in Q4 2025 and mid-2026, respectively.

Tangram’s innovative medicines are enabled by GalOmic, our proprietary RNAi chemistry platform designed to selectively silence disease-driving genes in hepatocytes. Discovery is powered by LLibra OS, our next-generation AI platform with an agentic infrastructure. The unique combination of these platforms is the foundation of our Relentless Medicine Discovery. Faster, smarter development of RNAi medicines designed for real-world impact.